Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Praluent neurocognitive function study
NCT02957682Phase 4Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2016
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 4, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia comparing Praluent Group with Placebo Group (2 arms). Primary endpoint: Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at 96 weeks. Started Nov 2016; status: completed.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)hypercholesterolemia
Beyond the preview
Go deeper on NCT02957682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02957682.